Will Studies in Nonalcoholic Steatohepatitis Help Manage Alcoholic Steatohepatitis?
Alcoholic cirrhosis
Alcoholic liver disease
Anti-fibrotic
Anti-inflammatory
Fatty liver disease
Journal
Clinics in liver disease
ISSN: 1557-8224
Titre abrégé: Clin Liver Dis
Pays: United States
ID NLM: 9710002
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
entrez:
21
11
2018
pubmed:
21
11
2018
medline:
17
9
2019
Statut:
ppublish
Résumé
Hepatic steatosis and steatohepatitis have several etiologies; the most common are alcoholic steatohepatitis (ASH) and obesity/metabolic syndrome-induced steatohepatitis, also known as nonalcoholic steatohepatitis (NASH). Although the etiology of these 2 conditions is different, they share pathways to disease progression and severity. They also have differences in physiologic pathways, and shared and divergent mechanisms can be therapeutic targets. There is no approved pharmacologic therapy for NASH, but several molecules are under study. Focus remains on modulation of insulin resistance, oxidative stress, the inflammatory cascade, hepatic fibrosis, and cell death. This review provides an overview of pathophysiologic similarities and differences between ASH and NASH.
Identifiants
pubmed: 30454829
pii: S1089-3261(18)30084-9
doi: 10.1016/j.cld.2018.09.008
pii:
doi:
Substances chimiques
Glucocorticoids
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
157-165Informations de copyright
Published by Elsevier Inc.